Covelli V, Munno I, Altamura M, Pellegrino N M, Decandia P, Jirillo E
Istituto di Clinica Neurologica, II Facoltà di Medicina e Chirurgia, Università di Napoli, Italy.
Immunopharmacol Immunotoxicol. 1990;12(4):619-31. doi: 10.3109/08923979009019680.
Seven patients with phobic disorders were administered with a synthetic thymic extract, thymopentin (TP-5), in order to correct depressed polymorphonuclear cell (PMN) and monocyte phagocytosis and killing capacities. Subcutaneous administration (50 mg, three times weekly, for a period of 8 wks) of TP-5 resulted in a significant increase in phagocytic function with no change in the phagocytic capacity of PMN. These data support the concept that immunomodulators can achieve a correction of immune deficiencies associated with phobic disorders.